Use of poloxamer polymers to stabilize recombinant human growth hormone against various processing stresses

Pharmaceutical Development and Technology

Volumn 2, Issue 2, 1997, Pages 143-149

  Katakam, Manohar ^a,b   Banga, Ajay K ^a  

^a AUBURN UNIVERSITY   (United States)

^b CENTOCOR INC   (United States)

Author keywords

Denaturation; Human growth hormone; Physical stability; Poloxamers

Indexed keywords

HUMAN GROWTH HORMONE; POLOXAMER; POLYMER;

ADSORPTION; ARTICLE; DRUG MANUFACTURE; DRUG STABILITY; FILTRATION; FREEZING; NEEDLE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DENATURATION; SHIPPING; TEMPERATURE; THAWING;

EID: 0031391073     PISSN: 10837450     EISSN: None     Source Type: Journal    
DOI: 10.3109/10837459709022619     Document Type: Article

References (19)

1. R. Pearlman and T. A. Bewley, Stability and characterization of human growth hormone, in Stability and Characterization of Protein Drugs: Case Histories (Y. J. Wang and R. Pearlman, eds.), Plenum Press, New York, 1993, pp. 1-58.
2. G. Backer, R. Bowsher, W. Mackellar, M. Poor, P. Tackitt, and R. Riggin, Chemical, physical, and biological characterization of a dimeric form of bio synthetic human growth hormone, Biotechnol. Appl. Biochem., 9, 478-487 (1987).
3. B. M. Eckhardt, J. Q. Oeswein, and T. A. Bewley, Effect of freezing on aggregation of human growth hormone, Pharm. Res., 8, 1360-1364 (1991).
4. S. A. Charman, K. L. Mason, and W. N. Charman, Techniques for assessing the effects of pharmaceutical excipients on the aggregation of porcine growth hormone, Pharm. Res., 10, 954-962 (1993).
5. M. Katakam, L. N. Bell, and A. K. Banga, Effect of surfactants on the physical stability of recombinant human growth hormone, J. Pharm. Sci., 84, 713-716 (1995).
6. S. Sato, C. D. Ebert, and S. W. Kim, Prevention of insulin self-association and surface adsorption, J. Pharm. Sci., 72, 228-232 (1983).
7. L. E. Kirsch, R. M. Riggin, D. A. Gearhart, D. S. Lefeber, and D. L. Lytle, In-process protein degradation by exposure to trace amounts of sanitizing agents, J. Parenter. Sci Technol., 47, 155-160 (1993).
8. P. W. Mantyh, J. R. Ghilardi, S. Rogers, E. Demaster, C. J. Allen, E. R. Stimson, and J. E.Maggio, Aluminum, iron and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide, J. Neurochem., 61, 1171-1174 (1993).
9. V. Sluzky, J. A. Tamada, A. M. Klibanov, and R. Langer, Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces, Proc. Natl. Acad. Sci. USA, 88, 9377-9381 (1991).
10. P. A. Kosen, Disulfide bonds in proteins, in Stability of Protein Pharmaceuticals. Part A: Chemical Physical Pathways of Protein Degradation (T. J. Ahern and M. C. Manning, eds.), Plenum, New York, 1992, pp.31-67.
11. A. Wade and P. J. Weller, in Handbook of Pharmaceutical Excipients, American Pharmaceutical Association, Washington, DC, 1994, pp. 352-354.
12. BASF Wyandotte Corp., Technical Data on Pluronic® Polyols No. OS796, Parsippany, NJ, 1975, pp. 1-11.
13. T. P. Johnston and S. C. Miller, Toxicological evaluation of poloxamer vehicles for intramuscular use, J. Parenter. Sci. Technol., 39, 83-88 (1985).
14. T. P. Johnston, M. A. Punjabi, and C. J. Froelich, Sustained delivery of interleukin-2 from a Poloxamer 407 gel matrix following intraperitoneal injection in mice, Pharm. Res., 9, 425-434 (1992).
15. K. A. Fults and T. P. Johnston, Sustained release of urease from a poloxamer gel matrix, J. Parenter. Sci. Technol., 44, 58-65 (1990).
16. P. Wang and T. P. Johnston, Enhanced stability of two model proteins in an agitated solution environment using Poloxamer 407, J. Parenter. Sci.Technol., 47, 73-81 (1993).
17. J. Q. Oeswein, A. L. Daugherty, E. J. Cornovaca, J. A. Moore, H. M. Gustafson, B. M. Eckhardt, H. J. Fichs, G.Keller, and J. S.Patton, Aerosolization of protein pharmaceuticals, in Proceedings of the Second Respiratory Drug Delivery Symposium (R. N. Dalby and R. Evans, eds.), Continuing Pharmacy Education, University of Kentucky, 1991, pp 14-49.
18. M. Mumunthaler, C. C. Hsu, and R. Pearlman, Feasibility study on spray-drying protein pharmaceuticals: Recombinant human growth hormone and tissue-type plasminogen activator, Pharm. Res., 11, 12-20 (1994).
19. H. Thurow and K. Geisen, Stabilization of dissolved proteins against denaturation at hydrophobic interfaces, Diabetologia, 27, 212-218 (1984).